The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price target of $150.00 ... corporate insider sentiment is ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

BioNTech (NASDAQ:BNTX – Get Free Report) will be announcing its earnings results before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of ($1.06) per share ...

Operator Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz ...

In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ ... as did their stock prices. But three years later, times have changed dramatically for both companies.

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

Shares of Pfizer (PFE) initially rose slightly after markets reacted to the firm’s quarterly results. By the end of the day yesterday, PFE stock lost 1.39%. Pfizer reported topline growth of $2.8 ...

Fintel reports that on November 8, 2024, Goldman Sachs upgraded their outlook for BioNTech SE - Depositary Receipt () ...